COMP <GO>
SGRY vs LLY // ALTMAN Z-SCORE & DEBT/EQUITY
Surgery Partners Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: SGRY 6
— LLY 9
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: LLY
LAST: $23.21 (0.00%) • MKT CAP: $3.04B
balance-sheet
0.67
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
balance-sheet
9.29
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SGRY VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SGRY | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 83.64% | -42.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | 32.36% | -22.46 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 9.7x | 36.4x | -26.72 | SGRY | /valuation <GO> |
| Free Cash Flow Yield | 6.44% | 2.30% | +4.14 | SGRY | /fcf-yield <GO> |
| Operating Margin | 45.80% | 40.21% | +5.59 | SGRY | /operating-margins <GO> |
| Net Profit Margin | -9.20% | 31.90% | -41.10 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 6.60% | 45.51% | -38.91 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 0.67 | 9.29 | -8.62 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.77% | +0.13 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 86.2 | 77.9 | +8.28 | SGRY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 0.51 | +0.48 | SGRY | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 26.3x | -4.25 | SGRY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.04B | $1.33T | -$1.33T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SGRY REV | LLY REV | SGRY GROSS % | LLY GROSS % | SGRY FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $65.18B | — | 83.0% | $195.6M | $16.81B |
| FY 2024 | $0 | $45.04B | — | 81.3% | $209.7M | $8.82B |
| FY 2023 | $0 | $34.12B | — | 79.3% | $293.8M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SGRY // BETA 0.99
LLY // BETA 0.51